Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Oct;10(5):493-7.
doi: 10.1097/ACI.0b013e32833dfa11.

High-risk corneal allografts and why they lose their immune privilege

Affiliations
Review

High-risk corneal allografts and why they lose their immune privilege

Jerry Y Niederkorn. Curr Opin Allergy Clin Immunol. 2010 Oct.

Abstract

Purpose of review: Corneal allografts are routinely performed without HLA typing or systemic immunosuppressive drugs. However, certain conditions create high risks for immune rejection. This review discusses recent insights into the mechanisms that rob the corneal allograft of its immune privilege.

Recent findings: Studies in mice have revealed that stimuli that induce new blood vessel growth in the cornea also elicit proliferation of lymph vessels. Lymph vessels facilitate migration of antigen-presenting cells to regional lymph nodes in which they induce alloimmune responses. The presence of blood vessels in the corneal graft bed creates a unique chemokine milieu that stimulates recruitment of sensitized lymphocytes into the corneal allograft. Other data indicate that although corneal allograft survival is closely associated with Foxp3 expression in CD4+CD25+Foxp3+ T regulatory cells (Tregs), reduced expression of Foxp3 in Tregs creates a high risk for graft rejection. Recent evidence indicates that allergic diseases have a profound impact on the immune response and produce a dramatic increase in corneal allograft rejection.

Summary: Understanding the underlying mechanisms that create 'high-risk' hosts may provide important therapeutic targets for restoring immune privilege of corneal allografts and enhancing their survival.

PubMed Disclaimer

Conflict of interest statement

The author has no conflicts of interest to report.

Similar articles

Cited by

References

    1. George AJ, Larkin DF. Corneal transplantation: The forgotten graft. Am J Transplant. 2004;4:678–685. - PubMed
    1. Niederkorn JY. The immune privilege of corneal allografts. Transplantation. 1999;67:1503–1508. - PubMed
    1. Niederkorn JY. The immune privilege of corneal grafts. J Leukoc Biol. 2003;74:167–171. - PubMed
    1. Niederkorn JY. Immune mechanisms of corneal allograft rejection. Curr Eye Res. 2007;32:1005–1016. - PubMed
    1. Group CCTSR. The collaborative corneal transplantation studies (CCTS) Effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol. 1992;110:1392–1403. - PubMed

Publication types

Substances